➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Baxter
Moodys
Colorcon
Medtronic
AstraZeneca

Last Updated: September 25, 2020

DrugPatentWatch Database Preview

Details for Patent: 8,969,336

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,969,336 protect, and when does it expire?

Patent 8,969,336 protects XOSPATA and is included in one NDA.

This patent has forty-three patent family members in twenty-six countries.

Summary for Patent: 8,969,336
Title:Diamino heterocyclic carboxamide compound
Abstract: Provided is a compound useful as an inhibitor against the kinase activity of EML4-ALK fusion protein. As a result of intensive and extensive studies on compounds having inhibitory activity against the kinase activity of EML4-ALK fusion protein, the present inventors found that the diamino heterocyclic carboxamide compounds of the present invention had inhibitory activity against the kinase activity of EML4-ALK fusion protein. By this finding, the present invention was completed. The compounds of the present invention can be used as a pharmaceutical composition for preventing and/or treating cancer, such as lung cancer, non-small cell lung cancer, and small cell lung cancer.
Inventor(s): Shimada; Itsuro (Tokyo, JP), Kurosawa; Kazuo (Tokyo, JP), Matsuya; Takahiro (Tokyo, JP), Iikubo; Kazuhiko (Tokyo, JP), Kondoh; Yutaka (Tokyo, JP), Kamikawa; Akio (Tokyo, JP), Tomiyama; Hiroshi (Nagano, JP), Iwai; Yoshinori (Nagano, JP)
Assignee: Astellas Pharma Inc. (Tokyo, JP) Kotobuki Pharmaceutical Co., Ltd. (Hanishina-gun, JP)
Application Number:13/266,164
Patent Claim Types:
see list of patent claims
Use; Composition; Compound;

Drugs Protected by US Patent 8,969,336

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Astellas XOSPATA gilteritinib fumarate TABLET;ORAL 211349-001 Nov 28, 2018 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,969,336

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan2009-113936May 8, 2009
PCT Information
PCT FiledMay 06, 2010PCT Application Number:PCT/JP2010/057751
PCT Publication Date:November 11, 2010PCT Publication Number: WO2010/128659

International Family Members for US Patent 8,969,336

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2010245545   Start Trial
Brazil PI1011838   Start Trial
Canada 2760061   Start Trial
China 102421761   Start Trial
Cyprus 1117546   Start Trial
Cyprus 1120367   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
McKesson
Boehringer Ingelheim
AstraZeneca
Moodys
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.